Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The abstract showcases the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML).
Lead Product(s): Natural Killer Cell,Filgrastim,Fludarabine Phosphate
Therapeutic Area: Oncology Brand Name: KDS-1001
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2020
Lead Product(s) : Natural Killer Cell,Filgrastim,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kiadis Pharma announces new data on ex-vivo FC21
Details : The abstract showcases the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML).
Product Name : KDS-1001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 03, 2020
Details:
Zefylti (filgrastim biosimilar) is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by recombinant DNA technology. It is indicated for the treatment of febrile neutropenia.
Lead Product(s): Filgrastim
Therapeutic Area: Hematology Brand Name: Zefylti
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2025
Lead Product(s) : Filgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Pharma Arm’s Biosimilar gets Marketing Nod from U.K.’s MHRA
Details : Zefylti (filgrastim biosimilar) is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by recombinant DNA technology. It is indicated for the treatment of febrile neutropenia.
Product Name : Zefylti
Product Type : Protein
Upfront Cash : Inapplicable
May 13, 2025
Details:
BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia.
Lead Product(s): Motixafortide,Filgrastim
Therapeutic Area: Oncology Brand Name: Aphexda
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Ayrmid
Deal Size: $97.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement November 21, 2024
Lead Product(s) : Motixafortide,Filgrastim
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Ayrmid
Deal Size : $97.0 million
Deal Type : Licensing Agreement
BioLineRx and Ayrmid Partner to Commercialize APHEXDA® Through Gamida Cell
Details : BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia.
Product Name : Aphexda
Product Type : Peptide
Upfront Cash : $10.0 million
November 21, 2024
Details:
The net proceeds will be used to advance the commercialization of APHEXDA (motixafortide) approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.
Lead Product(s): Motixafortide,Filgrastim
Therapeutic Area: Oncology Brand Name: Aphexda
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Blackrock
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 04, 2024
Lead Product(s) : Motixafortide,Filgrastim
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Blackrock
Deal Size : Undisclosed
Deal Type : Financing
BioLineRx Accesses Second Tranche of $20M Under $40M Non-Dilutive Debt Financing Agreement
Details : The net proceeds will be used to advance the commercialization of APHEXDA (motixafortide) approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.
Product Name : Aphexda
Product Type : Peptide
Upfront Cash : Undisclosed
October 04, 2024
Details:
BioLineRx plans to use proceeds for the commercialization of APHEXDA (motixafortide) in the U.S. for stem cell mobilization in multiple myeloma patients.
Lead Product(s): Motixafortide,Filgrastim
Therapeutic Area: Oncology Brand Name: Aphexda
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Jonestrading Institutional Services
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 04, 2024
Lead Product(s) : Motixafortide,Filgrastim
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Jonestrading Institutional Services
Deal Size : $6.0 million
Deal Type : Public Offering
BioLineRx Announces $6 Million Registered Direct Offering
Details : BioLineRx plans to use proceeds for the commercialization of APHEXDA (motixafortide) in the U.S. for stem cell mobilization in multiple myeloma patients.
Product Name : Aphexda
Product Type : Peptide
Upfront Cash : Undisclosed
January 04, 2024
Details:
RELEUKO® (filgrastim-ayow) is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. RELEUKO® in the U.S. is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies.
Lead Product(s): Filgrastim
Therapeutic Area: Hematology Brand Name: Releuko
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 22, 2022
Lead Product(s) : Filgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
Details : RELEUKO® (filgrastim-ayow) is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. RELEUKO® in the U.S. is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients w...
Product Name : Releuko
Product Type : Protein
Upfront Cash : Inapplicable
November 22, 2022
Details:
U.S. FDA approved biologics license application for RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen, to treat neutropenia which is commonly experienced by patients undergoing chemotherapy, acute myeloid leukemia and nonmyeloid malignancies.
Lead Product(s): Filgrastim
Therapeutic Area: Hematology Brand Name: Releuko
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Kashiv BioSciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 03, 2022
Lead Product(s) : Filgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Kashiv BioSciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
Details : U.S. FDA approved biologics license application for RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen, to treat neutropenia which is commonly experienced by patients undergoing chemotherapy, acute myeloid leukemia and nonmyeloid malignancies.
Product Name : Releuko
Product Type : Protein
Upfront Cash : Inapplicable
January 03, 2022
Details:
The study was designed to evaluate the safety and efficacy of Recardio's lead candidate dutogliptin to restore lost myocardial function in patients who experience STEMI, a severe form of heart attack, and receive percutaneous coronary intervention with stent placement.
Lead Product(s): Dutogliptin Tartrate,Filgrastim
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2021
Lead Product(s) : Dutogliptin Tartrate,Filgrastim
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recardio Completes Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin
Details : The study was designed to evaluate the safety and efficacy of Recardio's lead candidate dutogliptin to restore lost myocardial function in patients who experience STEMI, a severe form of heart attack, and receive percutaneous coronary intervention with s...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2021
Details:
Amneal Pharmaceuticals has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.
Lead Product(s): Filgrastim
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 04, 2021
Lead Product(s) : Filgrastim
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals
Details : Amneal Pharmaceuticals has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and no...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
May 04, 2021
Details:
In addition, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction & CHF, with the potential of improving heart function, quality of life & survival.
Lead Product(s): Dutogliptin Tartrate,Filgrastim
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2020
Lead Product(s) : Dutogliptin Tartrate,Filgrastim
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Interim Analysis of Recardio's Phase II Clinical Trial Published in European Heart Journal
Details : In addition, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction & CHF, with the potential of improving heart function, quality of life ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2020
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE